It's factor VIII with state-of-the-art purification.
It comes with all-in-one reconstitution.
Next-generation purification and 2 state-of-the-art
steps designed with viral safety in mind.
XYNTHA has been demonstrated in clinical trials
to work successfully and control bleeds with 1 or 2
infusions in patients with hemophilia A.
Please see Indication and Important Safety Information
for XYNTHA at the bottom of the page.
Get In and Get It
With the XYNTHA Trial Prescription
Program, eligible patients can receive
a one-time, 1-month supply up to 20,000 IU
of XYNTHA at no cost.*
*Terms and Conditions apply.
From HemMobile™ —a customizable logging
tool—to various financial resources* and social
networks, XYNTHA is all about helping patients
get what they need.
*Terms and Conditions apply.
WHAT IS XYNTHA?
XYNTHA® Antihemophilic Factor (Recombinant) is indicated in adults and children for the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for the prevention of bleeding during surgery in patients with hemophilia A.
XYNTHA does not contain von Willebrand factor and, therefore, is not indicated for von Willebrand's disease.
IMPORTANT SAFETY INFORMATION FOR XYNTHA
- Call your healthcare provider or go to the emergency department right away if you have any of the following symptoms because these may be signs of a serious allergic reaction: wheezing, difficulty breathing, chest tightness, turning blue (look at lips and gums), fast heartbeat, swelling of the face, faintness, rash, low blood pressure, or hives. XYNTHA contains trace amounts of hamster protein. You may develop an allergic reaction to these proteins. Tell your healthcare provider if you have had an allergic reaction to hamster protein.
- Call your healthcare provider right away if bleeding is not controlled after using XYNTHA; this may be a sign of an inhibitor, an antibody that may stop XYNTHA from working properly. Your healthcare provider may need to take blood tests to monitor for inhibitors.
- Across all clinical studies, the most common side effects (10% or more) with XYNTHA in adult and pediatric previously treated patients (PTPs) were headache (26% of subjects), joint pain (25%), fever (21%), and cough (11%). Other side effects reported in 5% or more of patients were: diarrhea, vomiting, weakness, and nausea.
- XYNTHA is an injectable medicine administered by intravenous (IV) infusion. You may experience local irritation when infusing XYNTHA after reconstitution in XYNTHA® SOLOFUSE®.
Please see full Prescribing Information for XYNTHA and XYNTHA SOLOFUSE.
Need help paying for your Pfizer medicines?
Pfizer RxPathwaysTM Program may be able to help, regardless of your insurance situation.
Call 1-888-327-7787 or visit PfizerRxPath.com.
Join Hemophilia Village today and get community news and resources sent to your mailbox or in-box.
App Store is a service mark of Apple Inc.
Android and Google Play are trademarks of Google Inc.
Marketed by Pfizer Inc.
The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a health care provider. All decisions about patient care must be made with a health care provider, considering the unique characteristics of the patient.
The product information provided in this site is intended for residents of the United States. The products discussed herein may have different product labeling in different countries.
You are leaving XYNTHA.com
You are leaving this website. Links to all outside websites are provided as a convenience to our visitors and do not imply an endorsement or recommendation by Pfizer. Pfizer accepts no responsibility or liability for the content or services of other websites.